美国FDA药品溶出方法数据库

药品通用名称	剂型	USP溶出装置	速度	溶出介质	介质体积	建议取样时间（分钟）	更新日期
Oseltamivir Phosphate	Capsule			Refer to FDA's Dissolution Guidance, 2018			2020/07/02
Osilodrostat Phosphate	Tablet			Refer to FDA's Dissolution Guidance, 2018			2021/08/19
Osimertinib Mesylate	Tablet			Refer to FDA's Dissolution Guidance, 2018			2020/07/02
Ospemifene	Tablet			Develop a dissolution method			2023/09/15
Oteseconazole	Capsule	II (Paddle) with sinker	75	Tier 1: Stage 1: 0.01N HCl; Stage 2: After 15 minutes, add 150 mL of 3.0% SLS Tier 2: Stage 1: Pepsin (750,000 units/L) in 0.01N HCl; Stage 2: After 15 minutes, add 150 mL of 3.0% SLS		20, 30, 45 and 60	2023/10/06
Oxandrolone	Tablet			Refer to USP			2023/02/09
Oxaprozin	Tablet			Refer to USP			2016/03/17
Oxazepam	Capsule			Refer to USP			2024/05/31
Oxcarbazepine	Suspension			Develop a dissolution method			2023/09/15
Oxcarbazepine	Tablet			Develop a dissolution method			2023/09/15
Oxcarbazepine	Tablet (Extended Release)			Develop a dissolution method			2023/09/15
Oxybutynin	Trans-dermal	Paddle over Disk (Apparatus 5)	50	Phosphate Buffer, pH 4.5 @ 32oC	900	1, 4, 24 hours	2007/01/03
Oxybutynin Chloride	Tablet (Extended Release)			Refer to USP			2015/12/24
Oxycodone	Capsule (Extended Release)	I (Basket)	100	22 mM Sodium Acetate buffer, pH 4.5 with 0.03% Tween 20	900	1, 2, 4, 6, 8, 12, 16, 20 and 24 hours	2016/07/28
Oxycodone HCl	Capsule			Refer to FDA's Dissolution Guidance, 2018			2020/07/02
Oxycodone HCl	Tablet			Refer to FDA's Dissolution Guidance, 2018			2020/07/02
Oxycodone HCl	Tablet (Extended Release)			Refer to USP			2016/03/17
Oxycodone HCl/ Naloxone HCl	Tablet (Extended Release)	II (Paddle)	50	Simulated Gastric Fluid [SGF, pH 1.2] without enzyme	900	0.25, 0.5, 1, 2, 4, 6, 8, 10 and 12 hours	2016/12/22
Oxymorphone HCl	Tablets			Refer to FDA's Dissolution Guidance, 2018			2020/07/02
Oxymorphone HCl	Tablet (Extended Release)	II (Paddle) with sinker	50	45 mM Phosphate Buffer, pH 4.5	900	1, 2, 4, 6, 8 and 10 hours	2014/02/14